Article Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD). 

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Manuscripts citing this dataset 

  • A multi-center randomized proof-of-concept clinical trial applying [¹⁸F] FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. 2010. DOI: 10.3233/JAD-2010-100939 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here 

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here 


Post a question or thought about this dataset here.